Cancer Research and Treatment

Cancer Research and Treatment Search

> Browse Articles > Search

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang

Cancer Res Treat. 2018;50(3):835-842. Published online August 29, 2017 DOI: https://doi.org/10.4143/crt.2017.303

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer

Shin Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo

Cancer Res Treat. 2018;50(3):720-728. Published online July 14, 2017 DOI: https://doi.org/10.4143/crt.2017.169

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok

Cancer Res Treat. 2018;50(3):691-700. Published online July 6, 2017 DOI: https://doi.org/10.4143/crt.2017.280

Cited By 2

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type

Hyun Jee Kim, Chan-Young Ock, Tae Min Kim, Sung Hee Lee, Ju-Yeun Lee, Sun hoi Jung, Yoon Sook Cho, Miso Kim, Bhumsuk Keam, Dong-Wan Kim, Il Han Kim, Dae Seog Heo

Cancer Res Treat. 2018;50(3):670-680. Published online July 3, 2017 DOI: https://doi.org/10.4143/crt.2017.051

Cited By 1

Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate

Yoojoo Lim, Jee Min Lim, Won Jae Jeong, Kyung-Hun Lee, Bhumsuk Keam, Tae-Yong Kim, Tae Min Kim, Sae-Won Han, Do Youn Oh, Dong-Wan Kim, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Seock-Ah Im

Cancer Res Treat. 2017;49(4):1033-1043. Published online April 7, 2017 DOI: https://doi.org/10.4143/crt.2016.413

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer

Miso Kim, Bhumsuk Keam, Tae-Min Kim, Hoon-Gu Kim, Jin-Soo Kim, Sung Sook Lee, Seong Hoon Shin, Min Kyoung Kim, Keon Uk Park, Dong-Wan Kim, Hwan Jung Yun, Jong Seok Lee, Dae Seog Heo

Cancer Res Treat. 2017;49(2):416-422. Published online July 28, 2016 DOI: https://doi.org/10.4143/crt.2016.121

Cited By 3

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma

Yongjun Cha, Yu Jung Kim, Se-Hoon Lee, Tae-Min Kim, Seung Hong Choi, Dong-Wan Kim, Chul-Kee Park, Il Han Kim, Jee Hyun Kim, Eunhee Kim, Byungse Choi, Chae-Yong Kim, In Ah Kim, Dae Seog Heo

Cancer Res Treat. 2017;49(1):129-140. Published online May 18, 2016 DOI: https://doi.org/10.4143/crt.2015.466

Cited By 1

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

Ryul Kim, Seokyung Hahn, Junghoon Shin, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo

Cancer Res Treat. 2016;48(3):907-916. Published online November 17, 2015 DOI: https://doi.org/10.4143/crt.2015.359

Cited By 6

VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma

Seongyeol Park, Soo Jeong Nam, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, J. Hun Hah, Tack-Kyun Kwon, Dong-Wan Kim, Myung-Whun Sung, Dae Seog Heo, Yung-Jue Bang

Cancer Res Treat. 2016;48(2):518-526. Published online July 14, 2015 DOI: https://doi.org/10.4143/crt.2015.093

Cited By 3

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

Jin Hyoung Kang, Myung-Ju Ahn, Dong-Wan Kim, Eun Kyung Cho, Joo-Hang Kim, Sang Won Shin, Xin Wang, Jong Seok Kim, Mauro Orlando, Keunchil Park

Cancer Res Treat. 2016;48(2):458-464. Published online October 14, 2015 DOI: https://doi.org/10.4143/crt.2015.135

Cited By 1

Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era

Hyerim Ha, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo

Cancer Res Treat. 2016;48(1):304-311. Published online April 9, 2015 DOI: https://doi.org/10.4143/crt.2014.339

Cited By 3

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients

Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo

Cancer Res Treat. 2016;48(1):88-97. Published online March 3, 2015 DOI: https://doi.org/10.4143/crt.2014.201

Cited By 5

Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer

Yun-Gyoo Lee, Eunyoung Lee, Inho Kim, Keun-Wook Lee, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo

Cancer Res Treat. 2015;47(4):670-675. Published online January 2, 2015 DOI: https://doi.org/10.4143/crt.2014.045

Cited By 11

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations

Sehhoon Park, Bhumsuk Keam, Se Hyun Kim, Ki Hwan Kim, Yu Jung Kim, Jin-Soo Kim, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo

Cancer Res Treat. 2015;47(4):630-637. Published online February 16, 2015 DOI: https://doi.org/10.4143/crt.2014.244

Cited By 4

Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute

Younak Choi, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo

Cancer Res Treat. 2015;47(4):555-563. Published online February 16, 2015 DOI: https://doi.org/10.4143/crt.2014.200

Cited By 14

The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer

June-Koo Lee, Dong-Wan Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Young-Joo Kim, Dae Seog Heo

Cancer Res Treat. 2015;47(2):182-188. Published online September 12, 2014 DOI: https://doi.org/10.4143/crt.2013.227

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo

Cancer Res Treat. 2014;46(4):323-330. Published online July 14, 2014 DOI: https://doi.org/10.4143/crt.2013.120

Cited By 10

A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy

Hee Yeon Lee, Hoon-Kyo Kim, Kyung Hee Lee, Bong-Seog Kim, Hong Suk Song, Sung Hyun Yang, Joon Hee Kim, Yeul Hong Kim, Jong Gwang Kim, Sang-We Kim, Dong-Wan Kim, Si-Young Kim, Hee Sook Park

Cancer Res Treat. 2014;46(1):19-26. Published online January 15, 2014 DOI: https://doi.org/10.4143/crt.2014.46.1.19

Cited By 3

Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer

Ji-Won Kim, Youngil Koh, Dong-Wan Kim, Yong-Oon Ahn, Tae Min Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang

Cancer Res Treat. 2013;45(4):325-333. Published online December 31, 2013 DOI: https://doi.org/10.4143/crt.2013.45.4.325

Cited By 17

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution

Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo

Cancer Res Treat. 2013;45(3):178-185. Published online September 30, 2013 DOI: https://doi.org/10.4143/crt.2013.45.3.178

Cited By 7

Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients

Joo Ho Lee, Hong-Gyun Wu, Hak Jae Kim, Dong-Wan Kim, Se-Hoon Lee, Tae Min Kim, Young Whan Kim, Dae Seog Heo

Cancer Res Treat. 2012;44(4):242-250. Published online December 31, 2012 DOI: https://doi.org/10.4143/crt.2012.44.4.242

Cited By 9

Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer

Tae Ryool Koo, Hong-Gyun Wu, J. Hun Hah, Myung-Whun Sung, Kwang-Hyun Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae-Seog Heo, Charn Il Park

Cancer Res Treat. 2012;44(4):227-234. Published online December 31, 2012 DOI: https://doi.org/10.4143/crt.2012.44.4.227

Cited By 3

Gemcitabine and Vinorelbine Combination Chemotherapy in Anthracycline- and Taxane-pretreated Advanced Breast Cancer

Hye Jin Kim, Jin-Soo Kim, Myung-Deok Seo, So-Yeon Oh, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang

Cancer Res Treat. 2008;40(2):81-86. Published online June 30, 2008 DOI: https://doi.org/10.4143/crt.2008.40.2.81

Cited By 5

Open-label, Randomized Comparison of the Efficacy of Intravenous Dolasetron Mesylate and Ondansetron in the Prevention of Acute and Delayed Cisplatin-induced Emesis in Cancer Patients

Jin-Soo Kim, Ji Yeon Baek, Sook Ryun Park, In Sil Choi, Sang-Il Kim, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim

Cancer Res Treat. 2004;36(6):372-376. Published online December 31, 2004 DOI: https://doi.org/10.4143/crt.2004.36.6.372

Cited By 2

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy

Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo

Received October 16, 2017 Accepted April 2, 2018 Published online April 5, 2018
DOI: https://doi.org/10.4143/crt.2017.491
[Epub ahead of print]

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer

Dong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, Keunchil Park, Hoon-Kyo Kim, Joung Soon Jang, Bong-Seog Kim, Jin-Hyoung Kang, Kyung Hee Lee, Sang-We Kim, Hun Mo Ryoo, Jin-Soo Kim, Ki Hyeong Lee, Jung Hye Kwon, Jin-Hyuk Choi, Sang Won Shin, Seokyung Hahn, Dae Seog Heo

Received January 5, 2018 Accepted March 8, 2018 Published online March 12, 2018
DOI: https://doi.org/10.4143/crt.2018.019
[Epub ahead of print]

Cited By 2

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

Seulki Kim, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Yong-Oon Ahn, Bhumsuk Keam, Dae Seog Heo

Received January 18, 2018 Accepted October 5, 2018 Published online October 10, 2018
DOI: https://doi.org/10.4143/crt.2018.052
[Accepted]